Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Increases Indirect Holdings Through Child Custodial Accounts

Director Jon Faiz Kayyem indirectly acquired shares of Inhibrx Biosciences through custodial accounts for his children.

Summary

• Jon Faiz Kayyem, a director at Inhibrx Biosciences, indirectly acquired 34,843 shares on November 19, 2024, at a weighted average price of $14.2269 per share through custodial accounts for each of his two children.
• On November 20, 2024, Kayyem indirectly acquired an additional 18,750 shares at a weighted average price of $14.1921 per share through custodial accounts for each of his two children.
• The total indirect holdings for each child increased to 69,843 shares after these transactions.
• The shares were purchased in multiple transactions at varying prices within the ranges of $14.09 to $14.25 on November 19 and $13.93 to $14.25 on November 20.

Sentiment

Score: 6

Explanation: The document is a routine filing of insider trading activity. It is neither particularly positive nor negative, but the director's purchase could be interpreted as a sign of confidence.

Positives

• The director's indirect purchase of shares could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade shares in their own company. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with the requirements of the Securities and Exchange Commission.
• The transactions are similar to those of other directors and officers who purchase shares in their own companies, often through various means such as open market purchases or option exercises.
• The use of custodial accounts for minor children is a common practice for estate planning and wealth transfer.

Stakeholder Impact

• The indirect purchase of shares by a director may be viewed positively by shareholders as a sign of confidence in the company.

Key Dates

Keywords

Inhibrx Biosciences, insider trading, Form 4, Jon Faiz Kayyem, custodial account, share acquisition, director, INBX